Regeneron And Bayer Report Positive Results For VEGF Trap-Eye In Second Phase 3 Study In Central Retinal Vein Occlusion
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer HealthCare announced positive top-line results for VEGF Trap-Eye (aflibercept ophthalmic solution) in the Phase 3 GALILEO study in patients with macular edema due to central retinal vein occlusion (CRVO)...